Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 332, pseudogene (RNU6-332P) is a *pseudogene* related to the U6 small nuclear RNA (snRNA) gene family[2][5]. U6 snRNA plays a fundamental role in the spliceosome as a noncoding RNA involved in the excision of introns from pre-mRNA in the nucleus of eukaryotic cells[1][3]. However, RNU6-332P itself is annotated as a pseudogene, meaning it is a nonfunctional copy that does not encode functional RNA and is not believed to have direct biological activity, enzymatic function, or therapeutic relevance[2][5]. Like other pseudogenes, it may reflect genomic duplication events or vestiges of evolutionary gene families but is generally not transcribed into a functional molecule. **Additional context:** - Not a therapeutic target: Pseudogenes like RNU6-332P do not encode active products and are not targeted by approved medications, nor do they have known interacting drugs, biomarker status, or documented roles in disease or safety profiles. - Potential confusion: Functional U6 snRNA (non-pseudogene) is essential for RNA splicing, but the pseudogene variant RNU6-332P has no such known functional or therapeutic roles[1][3][2]. - Common issue: Many U6 pseudogenes exist in the human genome due to the evolutionary importance and high copy number of U6-type sequences, but they rarely retain function[1][5]. **Summary for structuring:** RNU6-332P is a non-functional pseudogene of the U6 small nuclear RNA gene family. It is not a protein, enzyme, receptor, transcription factor, or otherwise considered a molecular target. No drugs, disease roles, or biomarkers are associated, and its only significance is as a genomic sequence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 332, pseudogene (RNU6-332P).